SAB Biotherapeutics prices $85 million public offering at $3.85 per share Mar 17, 2026 10:46PM
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants Mar 17, 2026 10:46PM
SAB Biotherapeutics (SABS) PT Lowered to $12 at Chardan Capital Markets Aug 8, 2025 08:23AM
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes Nov 14, 2023 07:30AM
SAB Biotherapeutics (SABS) Announces Private Placement of up to $130 Million Oct 2, 2023 07:31AM


Oct 2, 2023 07:30AM SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
Nov 5, 2021 08:03AM Chardan Capital Markets Starts SAB Biotherapeutics (SABS) at Buy
Oct 25, 2021 07:39AM SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company
Oct 25, 2021 07:39AM SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company